Cervical Cancer: Awareness and Equity

CE / CME

Improving Provider Awareness About Healthcare Equity: Improving All Patients’ Access to Care in Cervical Cancer

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: June 26, 2023

Expiration: June 25, 2024

Shannon N. Westin
Shannon N. Westin, MD, MPH, FASCO

Activity

Progress
1
Course Completed

References

  1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
  2. Small W Jr, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123:2404-2412.
  3. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Cancer stat facts: cervical cancer. seer.cancer.gov/statfacts/html/cervix.html. Accessed April 7, 2023.
  4. Kaiser Family Foundation. Cervical cancer incidence rate per 100,000 women by race/ethnicity. kff.org/other/state-indicator/cervical-cancer-rate-by-re. Accessed April 7, 2023.
  5. US Centers for Disease Control and Prevention. human papillomavirus (HPV). cdc.gov/hpv. Accessed April 7, 2023.
  6. Staples JN, Nelamangala SL, Morris S, et al. Exploring socio-demographic and geospatial variation in human papillomavirus vaccination uptake in Virginia. Vaccine. 2021;39:5385-5390.
  7. Daniel CL, Lawson F, Vickers M, et al. Enrolling a rural community pharmacy as a Vaccines for Children provider to increase HPV vaccination: a feasibility study. BMC Public Health. 2021;21:1266. 
  8. US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:674-686.
  9. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70:321-346.
  10. Johnson NL, Head KJ, Scott SF, et al. Persistent disparities in cervical cancer screening uptake: knowledge and sociodemographic determinants of Papanicolaou and human papillomavirus testing among women in the United States. Public Health Rep. 2020;135:483-491.
  11. Akinlotan M, Bolin JN, Helduser J, et al. Cervical cancer screening barriers and risk factor knowledge among uninsured women. J Community Health. 2017;42:770-778.
  12. Carrasquillo O, Seay J, Amofah A, et al. HPV self-sampling for cervical cancer screening among ethnic minority women in South Florida: a randomized trial. J Gen Intern Med. 2018;33:1077-1083.
  13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: cervical cancer. v.1.2023. nccn.org. Accessed April 7, 2023.
  14. Pembrolizumab [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; 2023.
  15. Tisotumab vedotin [prescribing information]. Bothell, WA: Seagen Inc; 2022.
  16. Fleming S, Schluterman NH, Tracy JK, et al. Black and White women in Maryland receive different treatment for cervical cancer. PLoS One. 2014;9:e104344.
  17. Uppal S, Chapman C, Spencer RJ, et al. Association of hospital volume with racial and ethnic disparities in locally advanced cervical cancer treatment. Obstet Gynecol. 2017;129:295-304.
  18. Farley JH, Hines JF, Taylor RR, et al. Equal care ensures equal survival for African-American women with cervical carcinoma. Cancer. 2001;91:869-873.
  19. Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470-1478.
  20. Chung H, Delord JP, Perets R, et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study. Presented at: 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 19-25, 2021. Abstract 41.
  21. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385:1856-1867.
  22. Monk BJ, Colombo N, Tewari KS, et al. Pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6. Oral presentation. Abstr 5500.
  23. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609-619.
  24. Esnaola NR. A blueprint for addressing cancer disparities. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Oral presentation. 
  25. Chatterjee S, Gupta D, Caputo TA, et al. Disparities in gynecological malignancies. Front Oncol. 2016;6:36.